An Open Label Pilot Study to Evaluate the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10 in Healthy Subjects and Subjects on Statins
Sponsor study identifier
interventional
50
1 country
1
Study Start
March 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Study Completion
June 2015
Actual (reported)The primary objective of this study is to assess the blood levels of Coenzyme Q10 in healthy subjects when administered Omega Q Plus® Resveratrol for 28 days.The secondary objective of the study is to determine if statin use has an impact on the blood levels of Coenzyme Q10 when administered Omega Q Plus® Resveratrol for 28 days. The safety objectives will include assessment of safety evaluations as determined by:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2015
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2015
Date type not reportedThis date has not been verified as actual or estimated.
March 3, 2015
Actual (reported)April 14, 2015
Actual (reported)June 2015
Actual (reported)June 2015
Actual (reported)To assess the blood levels of Coenzyme Q10 in healthy subjects when administered Omega Q Plus® Resveratrol for 28 days.
28 days
Change from Baseline in blood levels of Coenzyme Q10 at 28 days
28 days
Change from,14 days prior to Baseline, in safety blood chemistry parameters (glucose, creatinine, AST, ALT, GGT, bilirubin) at 28 days
42 days
Change from,14 days prior to Baseline, in vital signs at 28 days
42 days
Number of Participants with Adverse Events
42 days
Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
Omega Q Plus Resveratrol (with 50mg CoQ10)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
KGK Synergize Inc.
London, Ontario, N6A 5R8, Canada
Tetyana Pelipyagina, MD
KGK Science Inc.
First Submitted
March 3, 2015
First Posted
April 14, 2015
Study Start
March 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
June 2015
Actual (reported)Last Updated
September 23, 2015
Record last verified: 2015-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: